通过人工智能增强的数字协作护理模式改善IBS症状的首次现实证据
Stephen E Lupe1, Joseph M Olson2, Kendra Kamp3
1The Cleveland Clinic, Cleveland, Ohio, USA.
Neurogastroenterology and motility
|September 5, 2025
概括
一个新的数字协作护理模型 (DCCM) 显著改善了易怒肠综合征 (IBS) 的症状. 这种方法结合了多学科护理,营养和行为治疗,
科学领域:
- 胃肠病学
- 数字健康
- 行为科学
背景情况:
- 医疗系统面临的挑战是提供指导方针推的多学科治疗刺激性肠综合征 (IBS).
- 数字协作护理模型 (DCCM) 通过整合经验丰富的提供者和数字工具,为增强IBS管理提供了有前途的技术解决方案.
研究的目的:
- 评估新型DCCM在改善IBS症状的患者的临床结果方面的有效性.
- 评估综合护理途径,包括多学科团队,个性化营养和脑肠行为治疗对IBS症状严重性的影响.
主要方法:
- 一项前性,纵向,单臂研究评估了艾布尔健康计划,其中有202名参与者出现活跃的IBS症状 (IBS-SSS≥75).
- 参与者从事至少三个护理途径之一:多学科护理团队,个性化营养/消除饮食或脑肠行为治疗 (BGBT).
- 人工智能算法通过分析患者报告的结果和确定关键趋势来支持护理个性化.
主要成果:
- 在IBS症状严重度表 (IBS-SSS) 中,平均下降了140个点.
- 86%的参与者在IBS-SSS中实现了至少50分的临床意义上的降低.
- 在各个途径中发现了高参与率,其中98%参与营养,75%参与BGBT,77%参与护理团队;62%使用所有三种途径.
结论:
- 这种新型的DCCM有效地提供了基于证据的护理,导致活跃IBS患者的临床显著和持续的症状缓解.
- 这项研究强调了综合数字护理模式在治疗IBS方面的潜力.
- 建议进行进一步的随机临床试验,以比较标准治疗的成本效益和疗效.
相关概念视频
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
232
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
232
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
286
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
286
01:17Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289
01:17Irritable Bowel Syndrome I: Introduction
360
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
360
01:21Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
01:29Chronic Pancreatitis II: Collaborative Care
127
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
127